BeiGene
BGNE
$179.87
Share price
-2.33%
Change (1 day)
5.98%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
EPS for BeiGene (BGNE)
EPS in 2023 (TTM): -$16.64
According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$16.64. In 2022 the company made an earnings per share (EPS) of -$19.37 a decrease over its 2021 EPS that were of -$15.21.
EPS history for BeiGene from 2015 to 2023
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2023 (TTM) | -$16.64 | -14.09% |
| 2022 | -$19.37 | 27.35% |
| 2021 | -$15.21 | -19.96% |
| 2020 | -$19.00 | 20.81% |
| 2019 | -$15.73 | 31.52% |
| 2018 | -$11.96 | 417.57% |
| 2017 | -$2.31 | -37.16% |
| 2016 | -$3.68 | 158.95% |
| 2015 | -$1.42 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -$0.27 | -98.38% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -$1.00 | -93.99% | 🇺🇸 USA |